Experts from the Center for Genetic Engineering and Biotechnology (CIGB) and the Finlay Vaccine Institute presented the results of the clinical trials of Cuban vaccines against covid-19, developed by each of the institutions.
The Cuban regulatory authority also participated in the virtual meeting with experts from both institutions. Its director offered an explanation of the certification process for compliance with good clinical and manufacturing practices.
At the conclusion of the meeting, chaired by Dr. Mariângela Simão, WHO deputy director general, for access to Medicines, Vaccines and Pharmaceuticals, the next steps were agreed to continue the process for the recognition of Cuban vaccines.
Last Tuesday, Rolando Pérez Rodríguez, Director of Science and Innovation at BioCubaFarma commented at the Round Table that “there have already been some exchanges in Havana and at the office in Geneva. Now begins a procedure and a work exchange to evaluate the documentation submitted “.
However, he clarified that & nbsp; the regulatory agency of each country is the one that authorizes the use in the national territory, & nbsp; but that does not limit that it can be used in another nation; although, the recognition of the WHO opens more opportunities in the market.
Dr. Jarbas Barbosa Da Silva, Deputy Director of PAHO, recognized the efforts and results of Cuba in the development of vaccines against covid-19. He spoke of the importance of having these vaccines for our region and the world.
Source: Cubadebate
comments on